hotspot -WSS

hotspot

author：entertainment 2025-09-28 23:49:42 - browse：58618

Illustration of a red heart. -- health coverage from STAT — Adobe

Novo Nordisk’s obesity drug Wegovy cut the risk of major heart complications by 20% in a closely watched trial, results that could streamline insurance coverage and spur even greater demand for the highly popular therapy.

The milestone Select trial of about 17,500 patients is the first to show that an obesity medication leads to long-term cardiovascular benefits. The company reported only the topline figure in a press release Tuesday, and did not break out the reductions it said were seen in heart attacks, strokes, and cardiovascular deaths — the combined components of the study’s primary outcome. It said all three contributed to the decrease in cardiovascular events in the group that received Wegovy compared with participants given a placebo.

The 20% reduction was greater than many observers were expecting. In a research note Tuesday, Jefferies analysts called the results a “best case” outcome. “If they play baseball in Denmark,” Barclays analyst Emily Field wrote in a note, “Wegovy just hit a home run.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Change Healthcare cyberattack prompts Medicare loan program

Wikipedia

focus

WSS

Ukraine, Russia accuse each other of planning to attack Europe's biggest nuclear plant

Change Healthcare cyberattack prompts Medicare loan program

Grail is spending more than ever lobbying Congress

Ukraine, Russia accuse each other of planning to attack Europe's biggest nuclear plant

Make 'food is medicine' a key part of White House nutrition meeting

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

hotspot

hotspot

entertainment

Peter Hotez and the public health issue of online harassment

Grail is spending more than ever lobbying Congress

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Duchenne patients, backed by ‘dark money’ group, to debate drug prices

The high cost of giving birth even with insurance

Change Healthcare cyberattack prompts Medicare loan program

Alkermes shareholders re

IVF, abortion rights issues kick off Biden’s State of the Union

The cancer drug shortage isn’t new — and neither are the solutions

Change Healthcare payments predicted restored March 15

entertainment

A new study asks: Are we harming blood donors by taking blood?

Meta looks to target Twitter with a rival app called Threads

Doctor appointment wait times are getting worse

Grail is spending more than ever lobbying Congress

Amylyx ALS drug fails large clinical trial

NEJM study link tiny plastics in blood vessels to heart problems

focus

Wikipedia

focus

focus